FRANKFURT, Feb 5 (Reuters) - Bayer said on Thursday its experimental blood thinner cut the risk of stroke recurrence by 26% ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

Though Bayer Crop Science has spent more than $12 billion defending glyphosate, the company is optimistic a Supreme Court ...

Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

For years, a daily aspirin felt like a simple insurance policy for many adults who wanted to protect their hearts. Some ...